57. Idiopathic dilated cardiomyopathy
12 clinical trials,   25 drugs   (DrugBank: 12 drugs),   9 drug target genes,   33 drug target pathways
Searched query = "Idiopathic dilated cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01917149 (ClinicalTrials.gov) | March 2005 | 30/7/2013 | Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy | Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: Benazepril;Drug: Valsartan;Drug: Metoprolol | Xijing Hospital | NULL | Completed | 18 Years | 70 Years | Both | 480 | Phase 4 | China |
2 | NCT01798992 (ClinicalTrials.gov) | September 2000 | 22/2/2013 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart | Idiopathic Dilated Cardiomyopathy | Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin | University of Colorado, Denver | National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca | Completed | 18 Years | N/A | All | 56 | Phase 4 | United States |